Soleno Therapeutics, Inc. (SLNO) News

Soleno Therapeutics, Inc. (SLNO): $48.07

1.10 (-2.24%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add SLNO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#335 of 337

in industry

Filter SLNO News Items

SLNO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SLNO News Highlights

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

Latest SLNO News From Around the Web

Below are the latest news stories about SOLENO THERAPEUTICS INC that investors may wish to consider to help them evaluate SLNO as an investment opportunity.

Soleno Therapeutics, Inc. (NASDAQ:SLNO): When Will It Breakeven?

We feel now is a pretty good time to analyse Soleno Therapeutics, Inc.'s ( NASDAQ:SLNO ) business as it appears the...

Yahoo | January 7, 2025

Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC

Up to $200 million financing, includes $50 million upfrontREDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it has entered into a loan and security agreement with Oxford Finance LLC and its affiliates (Oxford) for up to $200 million. “This financing significantly strengthens our financial position, providing addition

Yahoo | December 17, 2024

High Growth Tech Stocks to Watch in November 2024

The United States market has shown robust performance recently, with a 2.0% increase over the last week and a substantial 32% climb in the past year, while earnings are projected to grow by 15% annually in the coming years. In this vibrant environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to maintain momentum alongside these promising market trends.

Yahoo | November 27, 2024

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time. A live audio webcast and replay of the fireside chat will be available in the Investors section on the

Yahoo | November 27, 2024

FDA delays decision of Soleno’s Prader-Willi syndrome drug

The new Prescription Drug User Fee Act (PDUFA) date for diazoxide choline extended-release (DCCR) is slated for 27 March 2025.

Yahoo | November 27, 2024

Kronos, Idorsia plan layoffs; PTC shelves ALS drug

Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC disclosed negative Phase 2 results for its ALS drug candidate utreloxastat.

Yahoo | November 27, 2024

Soleno Tumbles 17% as FDA Extends Review Timeline for Prader-Willi Treatment

Soleno's FDA review delay pushes action date to March 2025, prompting a 17% premarket stock decline

Yahoo | November 26, 2024

Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

PDUFA target action date extended by three months to March 27, 2025REDWOOD CITY, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Wi

Yahoo | November 26, 2024

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024

REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will be presenting data from its DCCR clinical development program for the treatment of Prader-Willi syndrome (PWS) at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2024, being held November 16-18, 2024 in Liverpool, UK. Detail

Yahoo | November 14, 2024

Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | November 12, 2024


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!